Navigation Links
Web-based Asthma Program Improves Disease Management for Black Students

Low-income African-American high school students with asthma who participated in a specially-designed, web-based disease management program reported fewer days and nights with symptoms, fewer school days missed, fewer days of restricted activity, and less hospitalization for asthma during a 12-month follow-up period, as compared to non-participating asthmatic students.

Christine L. M. Joseph, M.P.H, Ph.D., Senior Staff Epidemiologist for the Henry Ford Health System in Detroit, and 10 associates studied 314 mostly black students at six high schools in Detroit. Of the group, 162 students took part in four tailored web-based asthma intervention educational sessions. By contrast, a control group of 152 students had access to generic asthma websites.

The web-based program, which the researchers call Puff City, tried to teach the teenagers positive behaviors to help them better manage their asthma. It focused on three core behaviors: controller medication adherence, rescue inhaler availability and smoking cessation or reduction.

To our knowledge, our program is the first tailored, web-based multimedia asthma program for urban high school students evaluated in a non-clinic community setting, said Dr. Joseph. Results suggest that, for students in the treatment arm, functional status was significantly improved and the state of being diseased was significantly reduced when compared with a control group with access to generic asthma education websites.

During the study, the treatment group reported slightly less than one night of symptoms every two weeks, as contrasted with the control group, which reported 1.5 symptom nights. The treatment group missed less than half a school day every 30 days, while the control group missed 1.2 school days. Likewise, the treatment group experienced 1.3 days of restrictive activity every two weeks, in contrast to the control group at 2.3.

According to the authors, the nee
'"/>




Page: 1 2

Related medicine news :

1. New Drug for Bronchial Asthma
2. Asthma may actually be prevented by Dust and Dirt
3. Inhaled Steroids Safe & Effective for Children with Asthma
4. What happens when Asthmatics consume Aspirin?
5. Asthma! A new warning for heart disease
6. Asthma linked to obesity
7. Higher Risk of Asthma in children with autoimmune disease
8. Asthmatics at increased risk of lung cancer
9. Cleanliness might lead to Asthma
10. Asthma is not just a childhood condition
11. Asthma not just a childhood condition
Post Your Comments:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...s of hand-foot-mouth disease were reported in the ... of disaster relief George Chan Hong Nam said that...e days, bringing this year's total to more than 1,...uld not take this lightly, as the consequences can...
...ing pregnancy and childbirth are less likely to in...ing activities such as playing with their newborns...irst of its kind to analyze the impact of mother’s...practices, post partum. The researchers analyzed ...
...efects is improved by incorporation of folic acid ... known that folic acid supplementation during preg...th defects such as spina bifida, anencephaly etc. ...f consumption of folic acid fortified grains on ne...
... that the dreaded bird flu had made an entry into ...was confirmed that a cat had died of bird flu. Sin...sures to ward off the disease. // Federal Agricult...hofer has said that cats in the region of the bird...
Other Medicine News:Health News:Depressive Mothers Do Not Play Enough With Their Infants 2
(Date:10/2/2008)... STOCKHOLM, October 2 /- Athera Biot...unced today that they have entered into a,collabor...cts for the,prevention or treatment of cardiovascu...lows the recent publication of work by Athera,scie...e of the Karolinska,Institutet. The research links...
(Date:10/2/2008)... Data Indicate Dual Modes of Action and Synergy...rstCall/ -- Access Pharmaceuticals, Inc.,(OTC Bull...eclinical,studies on Angiolix showing that by bloc...enic effect as well as a direct anti-proliferative...s of human breast cancer (MX-1),Angiolix had a si...
(Date:10/1/2008)...ta support the therapeutic potential of Amylin,s i...to obesity pharmacotherapy, SAN DIEGO, Oct. 1 /PR.... (Nasdaq: AMLN ) today announced that new data f...ed at the 2008 Annual Scientific Meeting of The,Ob...Society,s annual,meeting is one of the largest and...
(Date:10/1/2008)...Intermezzo(R) (zolpidem tartrate sublingual lozeng...ly for use in the middle of the night when ...sleep, PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ ...ld specialty pharmaceutical company, announced tod...DA) to the U.S. Food and,Drug Administration (FDA)...
Breaking Medicine Technology:Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6Experts discuss climate change during UH lecture series 5081 1Experts discuss climate change during UH lecture series 5081 2Telik Announces Receipt of Nasdaq Notice 7927 1Telik Announces Receipt of Nasdaq Notice 7927 2Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 1Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 2Army can boost mission success by better managing 5076 1Army can boost mission success by better managing 5076 2Army can boost mission success by better managing 5076 3Army can boost mission success by better managing 5076 4
...trates Continued Safety for XIENCE V with No,Late ...ac Events,Out to Three Years, BARCELONA, Spain, Ma...ta from the SPIRIT FIRST trial demonstrated no,add...o late stent,thrombosis in patients treated with e...onary Stent System or its MULTI-LINK,VISION(R) met...
...2007 /PRNewswire-FirstCall/ -- Forest,Laboratories...d,that preliminary top-line results from a 1,196 p...ebo-controlled pivotal Phase III,study demonstrate...milnacipran as a treatment of fibromyalgia syndrom...to review initial top-line,results and further ana...
Other Medicine Technology:Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 2Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 3Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
...) is the sulfate ester of DHEA, derived from sulfa... in adrenal and extradrenal tissues. DHEA is the m...nd is a precursor for testosterone and estrogen bi...nic activity, which for unsulfated DHEA has been e...
...ompetition principle and the microplate separation...e and a fixed amount of DHEA-S conjugated with hor... of a polyclonal DHEA-S antiserum coated onto the ...te is washed to stop the competition reaction. Hav...
Inquire
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM.
Medicine Products: